No effect of carvedilol on nitric oxide generation in phagocytes but modulation of production of superoxide ions

被引:21
作者
Åsbrink, S
Zickert, A
Bratt, J
Gyllenhammar, H
Palmblad, J [1 ]
机构
[1] Huddinge Univ Hosp, Clin Res Ctr, Dept Med, Ctr Inflammat & Hematol Res, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Clin Res Ctr, Dept Hematol, Ctr Inflammat & Hematol Res, S-14186 Huddinge, Sweden
[3] Huddinge Univ Hosp, Clin Res Ctr, Dept Rheumatol, Ctr Inflammat & Hematol Res, S-14186 Huddinge, Sweden
关键词
neutrophils; nitric oxide; superoxide ions; chemotaxis; endothelial cells; carvedilol;
D O I
10.1016/S0006-2952(99)00393-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Since carvedilol has been claimed to possess antioxidative effects, this drug might affect functional responses, including nitric oxide (NO) generation, of polymorphonuclear neutrophils (PMN) and macrophages. When we assessed the effects of carvedilol on PMN responses in vitro, we observed that carvedilol dose dependently modulated generation of superoxide ions by NADPH oxidase when induced by the formylpeptide formyl-methionyl-leucyl-phenylalanine (fMLP) or the phorbol ester phorbol myristate acetate. This effect was not coupled to diminished phospholipase C activity. In contrast to the effect on NADPH oxidase, neither the fMLP-elicited NO generation by PMN nor the response of the murine macrophage cell line J774 to lipopolysaccharide was affected. There was no evidence from cell-free assay systems that carvedilol is a scavenger for superoxide ions or NO. Moreover, carvedilol did not affect other reactions dependent on NO, e.g. spontaneous or fMLP-stimulated PMN migration or lipoxin A(4)-, fMLP-, or A23187-induced neutrophil cytotoxicity for human umbilical vein endothelial cells. Thus, these effects point to the possibility that carvedilol modulates the NADPH oxidase of PMN but leaves the nitric oxide synthase of phagocytes intact. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:1007 / 1013
页数:7
相关论文
共 28 条
[11]   ANALYSIS OF NITRATE, NITRITE, AND [N-15]-LABELED NITRATE IN BIOLOGICAL-FLUIDS [J].
GREEN, LC ;
WAGNER, DA ;
GLOGOWSKI, J ;
SKIPPER, PL ;
WISHNOK, JS ;
TANNENBAUM, SR .
ANALYTICAL BIOCHEMISTRY, 1982, 126 (01) :131-138
[13]  
HARVATH L, 1984, J IMMUNOL, V133, P1471
[14]   Stimulus-dependent transduction mechanisms for nitric oxide release in human polymorphonuclear neutrophil leukocytes [J].
Lärfars, G ;
Gyllenhammar, H .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1998, 132 (01) :54-60
[15]   Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes [J].
Lärfars, G ;
Lantoine, F ;
Devynck, MA ;
Palmblad, J ;
Gyllenhammar, H .
BLOOD, 1999, 93 (04) :1399-1405
[16]   MEASUREMENT OF METHEMOGLOBIN FORMATION FROM OXYHEMOGLOBIN - A REAL-TIME, CONTINUOUS ASSAY OF NITRIC-OXIDE RELEASE BY HUMAN POLYMORPHONUCLEAR LEUKOCYTES [J].
LARFARS, G ;
GYLLENHAMMAR, H .
JOURNAL OF IMMUNOLOGICAL METHODS, 1995, 184 (01) :53-62
[17]   DEVELOPMENT AND CHARACTERIZATION OF ESSENTIAL FATTY-ACID DEFICIENCY IN HUMAN ENDOTHELIAL-CELLS IN CULTURE [J].
LERNER, R ;
LINDSTROM, P ;
BERG, A ;
JOHANSSON, E ;
ROSENDAHL, K ;
PALMBLAD, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (04) :1147-1151
[18]   CARVEDILOL, A NEW BETA-ADRENOCEPTOR BLOCKER ANTIHYPERTENSIVE DRUG, PROTECTS AGAINST FREE-RADICAL-INDUCED ENDOTHELIAL DYSFUNCTION [J].
LOPEZ, BL ;
CHRISTOPHER, TA ;
YUE, TL ;
RUFFOLO, R ;
FEUERSTEIN, GZ ;
MA, XL .
PHARMACOLOGY, 1995, 51 (03) :165-173
[19]   Chemotaxis by human neutrophils and their cytokineplasts treated with inhibitors of nitric oxide synthase: No suppression of orientation or trajectory [J].
Malawista, SE ;
Chevance, AD .
JOURNAL OF LEUKOCYTE BIOLOGY, 1997, 61 (01) :58-62
[20]   The effect of carvedilol on morbidity and mortality in patients with chronic heart failure [J].
Packer, M ;
Bristow, MR ;
Cohn, JN ;
Colucci, WS ;
Fowler, MB ;
Gilbert, EM ;
Shusterman, NH .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (21) :1349-1355